Segmed Deepens Verily Ties and Doubles Down on Privacy-Focused Data Infrastructure for Healthcare AI

Segmed intensified its positioning in healthcare AI this week, spotlighting data quality, privacy and regulatory compliance as core differentiators. The company also broadened its ecosystem reach via a collaboration with Alphabet unit Verily to expand access to biomedical data infrastructure for researchers.

Under the Verily partnership, Segmed is contributing longitudinal, real-world imaging data linked with structured clinical information. The data will be available through a new free self-serve Standard tier on Verily’s Pre Exchange and Workbench platforms, aiming to increase secure, compliant access for academic, clinical and industry users.

Segmed emphasized that its imaging datasets are de-identified and designed to be regulatory-grade, targeting use cases in precision health, AI development and translational research. While financial terms were not disclosed, the Verily integration could boost Segmed’s visibility and data usage within a large, Alphabet-affiliated ecosystem.

In parallel, Segmed promoted new blogs detailing its privacy-focused approach to medical imaging data, highlighting techniques such as DICOM de-identification, encryption and differential privacy. The material underscored alignment with HIPAA, GDPR and PIPEDA, positioning the firm as a compliant data-as-a-service provider in a tightly regulated market.

Additional content showcased Segmed’s broader data-infrastructure strategy, stressing that healthcare imaging AI performance depends more on curated, standardized and high-quality data than on algorithms alone. The company is building a multi-modal environment integrating radiology, pathology, cardiology, EHR data and genomics under strict security and governance controls.

Segmed also amplified its scientific profile through a strong presence at the European Congress of Radiology 2026, contributing to award-winning research and discussions on bias, AI reliability and multimodal data. Collectively, these moves reinforce Segmed’s role at the intersection of clinical-grade data and AI validation, supporting its long-term prospects in healthcare AI despite the lack of near-term financial disclosures.